RAS PATHWAY HYPERACTIVATION IS ASSOCIATED WITH INFERIOR SURVIVAL IN PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA
EHA Learning Center, Klaus Geissler, 214472
UNEXPECTED PREVALENCES OF THE JAK2V617F AND CALR MUTATIONS IN THE GENERAL POPULATION
EHA Learning Center, Sabrina Cordua, 214616
FINAL RESULTS OF A PHASE IB STUDY OF ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA.
EHA Learning Center, Joseph Mikhael, 214463
DECREASED INCIDENCE OF INFECTION, USE OF ANTIBACTERIALS AND DAYS IN HOSPITAL AFTER ADMINISTRATION OF CLT-008 MYELOID PROGENITOR CELLS TO SUBJECTS RECEIVING AML INDUCTION THERAPY: PHASE 2 STUDY RESULTS
EHA Learning Center, Pinkal Desai, 214467
ATRA COULD CORRECT THE IMPAIRED PROPLATELET FORMATION CAUSED BY THE TUBULIN Β1 SINGLE NUCLEOTIDE POLYMORPHISM R307H IN CORTICOSTEROID-RESISTANT ITP PATIENTS
EHA Learning Center, Chen-cong Wang, 214474
A PHASE 1, OPEN-LABEL STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ESCALATING DOSES OF LJPC-401 (SYNTHETIC HUMAN HEPCIDIN) IN PATIENTS WITH IRON OVERLOAD
EHA Learning Center, Vip Viprakasit, 214475
EFFICACY OF VENETOCLAX MONOTHERAPY IN PATIENTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA POST BTK INHIBITION THERAPY.
EHA Learning Center, Toby Eyre, 214548
IBRUTINIB DOES NOT SUPPRESS CLONAL EVOLUTION IN HIGH RISK CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Davide Rossi, 214554
PREDICTION OF LEUKEMIA FREE SURVIVAL FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION IN AML: A RISK SCORE DEVELOPED BY THE ALWP OF THE EBMT
EHA Learning Center, Roni Shouval, 214557
COMPARED ANALYSIS OF MUTATIONAL LANDSCAPE IN PEDIATRIC AND ADULT PATIENT WITH MYELODYSPLASTIC SYNDROMES
EHA Learning Center, Wenbin An, 214558
CALRETICULIN DEL52 KNOCK-IN MICE DEVELOP A DOSE-DEPENDENT THROMBOCYTOSIS AND PROGRESSION TO MYELOFIBROSIS
EHA Learning Center, Caroline Marty, 214560
GENOMIC LANDSCAPE OF ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA
EHA Learning Center, Li-Xin Wu, 214610
PHASE 1 FIRST-IN-HUMAN TRIAL OF AMV564, A BIVALENT BISPECIFIC (2×2) CD33/CD3 T-CELL ENGAGER, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, Peter Westervelt, 214466
KD025-208: A PHASE 2 OPEN-LABEL TRIAL OF KD025-208 FOR STEROID-DEPENDENT CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD)
EHA Learning Center, Madan Jagasia, 214470
EFFECTS OF BONE MARROW MESENCHYMAL CELLS FROM IMMUNE THROMBOCYTOPENIA PATIENTS ON THE BIOLOGICAL BEHAVIORS OF MEGAKARYOCYTES
EHA Learning Center, Hua Zhong, 214473
CO-OCCURRENCE OF STAG2 AND RAS SIGNALING MUTATIONS DURING PROGRESSION FROM MDS TO SAML ANALYZED BY WHOLE-EXOME AND TARGETED-DEEP SEQUENCING
EHA Learning Center, Marta Martín Izquierdo, 214496
A HISTIDINE PATCH IN THE N-DOMAIN OF MUTANT CALRETICULIN IS REQUIRED FOR MPN PATHOGENESIS
EHA Learning Center, Jeanne Rivera, 214497
ONCE-WEEKLY VS TWICE-WEEKLY CARFILZOMIB DOSING PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS OF THE RANDOMIZED PHASE 3 STUDY A.R.R.O.W.
EHA Learning Center, Maria Victoria Mateos, 214544
PROSPECTIVE PHASE II STUDY OF VENETOCLAX (VEN) IN PATIENTS (PTS) WITH PREVIOUSLY TREATED WALDENSTROM MACROGLOBULINEMIA (WM)
EHA Learning Center, Jorge CASTILLO, 214547
SYK TARGETING AS A POTENTIAL THERAPEUTIC STRATEGY FOR HIGH RISK TEL-AML1 PATIENTS
EHA Learning Center, Valentina Serafin, 214553
DEVELOPMENT OF A GALNAC SIRNA CONJUGATE TARGETING TMPRSS6 FOR THE TREATMENT OF IRON OVERLOAD DISORDERS, SUCH AS B-THALASSEMIA
EHA Learning Center, Ute Schaeper, 214565
MOR202 WITH LOW-DOSE DEXAMETHASONE (DEX) OR POMALIDOMIDE/DEX OR LENALIDOMIDE/DEX IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): A PHASE I/IIA, MULTICENTER, DOSE-ESCALATION STUDY
EHA Learning Center, Marc Raab, 214462
ACALABRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA
EHA Learning Center, Roger Owen, 214464
REGULATION OF HIF-1Α IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET
EHA Learning Center, Marta Coscia, 214468
PANOBINOSTAT, DECITABINE, AND DONOR LYMPHOCYTE INFUSION POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: THE HOVON 116 STUDY IN NEWLY DIAGNOSED POOR-RISK AML PATIENTS
EHA Learning Center, Jan Cornelissen, 214550
GRAFT-VERSUS-LEUKEMIA EFFECTS IN SECONDARY ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT
EHA Learning Center, Frederic Baron, 214556
DELETION OF STAT2 INCREASES THROMBOCYTOSIS AND SURVIVAL IN A JAK2 V617F MOUSE MODEL OF MPN VIA A NON CELL-AUTONOMOUS MECHANISM.
EHA Learning Center, Gaëlle Vertenoeil, 214559
LIVER IRON CONTENT DETERMINES HEPCIDIN LEVELS
EHA Learning Center, Sandro Altamura, 214564
MODELING HIGH RISK ACUTE LEUKEMIA WITH COMBINED T-CELL AND MYELOID PHENOTYPE CAUSED BY THE ETV6-NCOA2 FUSION GENE
EHA Learning Center, Hila Fishman, 214609
EZH2 AND RUNX1 MUTATIONS COLLABORATE TO INITIATE DISTINCT HEMATOLOGICAL MALIGNANCIES DEPENDING ON THE TARGET CELL
EHA Learning Center, Christopher Booth, 214614
NLRP3 INFLAMMSOME ACTIVATION IN PBMCS CONTROLS THE T CELL RESPONSE IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA
EHA Learning Center, Mingqiang Hua, 214617
OPTIMISMM: PHASE 3 TRIAL OF POMALIDOMIDE, BORTEZOMIB, AND LOW‐DOSE DEXAMETHASONE VS BORTEZOMIB AND LOW-DOSE DEXAMETHASONE IN LENALIDOMIDE-EXPOSED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Paul Richardson, 214461
ADMINISTRATION OF BPX-501 CELLS FOLLOWING ALPHA/BETA T-CELL AND B-CELL-DEPLETED HLA HAPLOIDENTICAL HSCT (HAPLO-HSCT) IN CHILDREN WITH PRIMARY IMMUNODEFICIENCIES
EHA Learning Center, Daria Pagliara, 214469
MULTINATIONAL, RANDOMIZED PHASE 3 TRIAL OF IBRUTINIB-RITUXIMAB VS PLACEBO-RITUXIMAB IN PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIA.
EHA Learning Center, Meletios A Dimopoulos, 214546
PROSPECTIVE STUDY OF HLA-MATCHED DONOR AVAILABILITY AND SURVIVAL IN REMISSION AFTER AML IN OLDER ADULTS: 1ST PLANNED ANALYSIS FROM ECOG-ACRIN E2906 PHASE III RANDOMIZED TRIAL IN PATIENTS AGE ≥60 YEARS
EHA Learning Center, James Foran, 214549
PIGGYBAC TRANSPOSON SCREENING IDENTIFIES NOVEL CANCER GENES AND REGULATORY ELEMENTS IN T CELL LEUKEMIA
EHA Learning Center, Anja Pfaus, 214552
A STRATEGY WITH CHAPERONE-LIKE COMPOUNDS TO RESTORE EXPRESSION OF FACTOR IX VARIANTS AFFECTED BY FREQUENT MISSENSE MUTATIONS CAUSING HEMOPHILIA B
EHA Learning Center, Mirko Pinotti, 214561
INVESTIGATING THE ROLE OF NCOA4 IN ACUTE AND CHRONIC IRON RELEASE FROM STORES
EHA Learning Center, Antonella Nai, 214563
MULTIPLE MECHANISMS OF KRAS ACTIVATION IN TRISOMY 12 CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Elena Vendramini, 214612
INTRINSIC DEFECTS CAUSED BY COMBINED CSNK1A1/RPS14 AND MIRNA145/146A DEFICIENCY DIRECTLY ALTER THE MICROENVIRONMENT IN A NOVEL MOUSE MODEL FOR DEL(5Q) MDS
EHA Learning Center, Flavia Ribezzo, 214613
A NOVEL INHIBITORY MUTATION FOR JAK2 V617F TARGETING THE AROMATIC INTERACTION AROUND F617 RESTORES NORMAL FUNCTION FOR MOST OF JAK2-UTILIZING CYTOKINE RECEPTORS EXCEPT IFNGR
EHA Learning Center, Emilie Leroy, 214615
Bispecific antibodies for ALL
EHA Learning Center, Christina Peters, 219185
CART cells
EHA Learning Center, Franco Locatelli, 219186
The imperative for change in adverse event reporting in hematologic malignancies
EHA Learning Center, Gita Thanarajasingam, 219187
Using patient-reported outcomes to improve toxicity assessment
EHA Learning Center, Fabio Efficace, 219188
Toxicity in hematologic malignancies: Considerations in bone marrow transplant, survivors and real world hematology patients
EHA Learning Center, John Gribben, 219189
Time trends in incidence rates of venous thrombosis
EHA Learning Center, Sigrid Braekkan, 219191
Future challenges in prevention and treatment of venous thrombosis
EHA Learning Center, John-Bjarne Hansen, 219192
Non-intensive treatment strategies in AML
EHA Learning Center, Gert Ossenkoppele, 219195
Intensive chemotherapy regimens in acute myeloide leukemia
EHA Learning Center, Je-Hwan Lee, 219196
QUIZARTINIB SIGNIFICANTLY PROLONGS OVERALL SURVIVAL IN PATIENTS WITH FLT3-INTERNAL TANDEM DUPLICATION–MUTATED (MUT) RELAPSED/REFRACTORY AML IN THE PHASE 3, RANDOMIZED, CONTROLLED QUANTUM-R TRIAL
EHA Learning Center, Jorge Cortes, 218882
Jean Bernard Lifetime Achievement Award: Lecture
EHA Learning Center, Charolotte Niemeyer, 219180
José Carreras Award lecture: Research challenges and therapeutic perspectives in APL
EHA Learning Center, Francesco Lo Coco, 219182
Autoimmunity checkpoints as therapeutic targets in B-cell malignancies
EHA Learning Center, Markus Müschen, 219183
ATEZOLIZUMAB PLUS R-CHOP SHOWS ENCOURAGING ACTIVITY AND ACCEPTABLE TOXICITY IN PREVIOUSLY UNTREATED PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): AN INTERIM ANALYSIS OF A PHASE I/II STUDY
EHA Learning Center, Anas Younes, 214450
A PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UMBRALISIB (TGR-1202) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO ARE INTOLERANT TO PRIOR BTK OR PI3K DELTA INHIBITOR THERAPY
EHA Learning Center, Anthony R. Mato, MD, 214453
RECENT PROGRESS IN GENE THERAPY FOR SEVERE SICKLE CELL DISEASE: UPDATED INTERIM RESULTS FROM A PHASE 1 CLINICAL STUDY OF LENTIGLOBIN GENE THERAPY
EHA Learning Center, Julie Kanter, 214456
A NOVEL BAEVRLESS-PSEUDOTYPED GLOBIN LENTIVIRAL VECTOR DRIVES HIGH AND STABLE FETAL HEMOGLOBIN EXPRESSION IMPROVING THALASSEMIC ERYTHROPOIESIS IN VITRO
EHA Learning Center, Nicholas P Anagnou, 214460
RAS MUTATIONS ARE THE DOMINANT MECHANISM OF SECONDARY RESISTANCE TO GILTERITINIB THERAPY FOR RELAPSED/REFRACTORY FLT3-MUTATED AML
EHA Learning Center, Christine M McMahon, 214486
THE ROLE OF DONOR CLONAL HEMATOPOIESIS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Mareike Frick, 214494
ESTABLISHMENT OF A SIMPLE RISK SCORE TO PREDICT SYSTEMIC MASTOCYTOSIS (SM) IN ADULT PATIENTS WITH MASTOCYTOSIS IN THE SKIN (MIS)
EHA Learning Center, David Fuchs, 214527
EVIDENCE FOR INTERCLONAL TUMOR COOPERATIVITY IN MEDIATING IBRUTINIB RESISTANCE BY BTK-C481SER EXPRESSING MYD88 MUTATED LYMPHOMA CELLS
EHA Learning Center, Guang Yang, 214536
THE RIBOSOMAL RPL10 R98S MUTATION DRIVES IRES-DEPENDENT BCL-2 TRANSLATION IN T-ALL
EHA Learning Center, Kim Kampen, 214606
PULMONARY EMBOLISM SEVERITY INDEX (PESI) SCORE AS A PREDICTOR FOR READMISSION IN ACUTE PULMONARY EMBOLISM IN EMERGENCY DEPARTMENT?
EHA Learning Center, Dwip Prajapati, 214608
IMPAIRMENT OF THE MESENCHYMAL STROMAL NICHE OF BETA-THALASSEMIA PATIENTS: IMPLICATIONS OF PROLONGED IRON EXPOSURE
EHA Learning Center, Stefania Crippa, 214459
ADDING POLATUZUMAB VEDOTIN (POLA) TO BENDAMUSTINE AND RITUXIMAB (BR) TREATMENT IMPROVES SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: RESULTS OF A PHASE 2 CLINICAL TRIAL
EHA Learning Center, Laurie Sehn, 214489
A PHASE IB/II STUDY OF DUVELISIB IN COMBINATION WITH FCR (DFCR) FOR FRONTLINE THERAPY OF YOUNGER CLL PATIENTS
EHA Learning Center, Matthew Davids, 214523
PHASE 2 STUDY OF RUXOLITINIB IN COMBINATION WITH 5-AZACITIDINE IN PATIENTS WITH MYELOFIBROSIS
EHA Learning Center, Lucia Masarova, 214526
PATIENTS’ ABILITY TO INDUCE APOPTOSIS IN MSC PREDICTS CLINICAL RESPONSES IN GRAFT-VERSUS-HOST DISEASE
EHA Learning Center, Antonio Galleu, 214530
COMPREHENSIVE SCREENING OF B-OTHER ADULT ALL PATIENTS TREATED ON UKALL14 ESTIMATES FREQUENCY AND PROGNOSTIC IMPACT OF GENE ALTERATIONS AND IDENTIFIES JAK-STAT ABNORMALITIES AS MARKERS OF POOR OUTCOME.
EHA Learning Center, Anthony Moorman, 214532
REFINING DIFFUSE LARGE B CELL LYMPHOMA SUBGROUPS USING INTEGRATED ANALYSIS OF MULTI-LEVEL MOLECULAR PROFILES IN A PROSPECTIVE COHORT: A LYSA STUDY
EHA Learning Center, Sydney Dubois, 214535
CART19-BE-01: A EUROPEAN ACADEMIC TRIAL ON THE USE OF ARI-0001 CELLS (A3B1:CD8:4-1BB:CD3Z CAR19 CELLS) IN PATIENTS WITH CD19+ RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Julio Delgado, 214539
A SYSTEMATIC REVIEW OF PREDICTORS OF VENOUS THROMBOEMBOLISM IN ACUTE LEUKEMIA
EHA Learning Center, Alejandro Lazo-Langner, 214541
INVESTIGATING THE ROLE OF INPP4B AS A THERAPEUTIC TARGET IN AML
EHA Learning Center, John Woolley, 214604
AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH REFRACTORY LARGE B CELL LYMPHOMA: OUTCOMES BY PRIOR LINES OF THERAPY IN ZUMA-1
EHA Learning Center, Olalekan O. Oluwole, 214449
HIGH RECURRENCE OF FUSION GENES IN PHILADELPHIA-LIKE CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Grazia Fazio, 214454
EFFECT OF COVARIATES IN THE PHARMACOKINETIC/PHARMACODYNAMIC MODEL OF ANDEXANET ALFA USED TO PREDICT THE REGIMEN FOR REVERSAL OF ANTICOAGULATION BY FXA INHIBITORS IN PATIENTS WITH ACUTE MAJOR BLEEDING
EHA Learning Center, Janet M. Leeds, 214457
IMPROVEMENTS IN HEMOGLOBIN, QUALITY OF LIFE, AND SIX-MINUTE-WALK DISTANCE IN ADULTS WITH Β-THALASSEMIA TREATED WITH LUSPATERCEPT: LONG-TERM PHASE 2 STUDY
EHA Learning Center, Antonio Piga, 214458
IBRUTINIB LEAD-IN FOLLOWED BY VENETOCLAX IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: PHASE 2 CAPTIVATE EARLY SAFETY AND EFFICACY RESULTS
EHA Learning Center, Paolo GHIA, 214522
THE EUTOS LONG-TERM SURVIVAL (ELTS) SCORE IS SUPERIOR TO THE SOKAL SCORE FOR PROGNOSIS OF SURVIVAL PROBABILITIES OF PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKAEMIA
EHA Learning Center, Markus Pfirrmann, 214525
PIM1 INHIBITION EFFECTIVELY ENHANCES AMD3100-INDUCED HSC MOBILIZATION
EHA Learning Center, Tony Müller, 214529
LONG-TERM OUTCOME OF A COHORT OF ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS, NOT ELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION, INFUSED WITH ALLOREACTIVE NATURAL-KILLER CELLS AS CONSOLIDATION THERAPY
EHA Learning Center, Sarah Parisi, 214538
UPDATED SAFETY & LONG TERM CLINICAL OUTCOMES IN TRANSCEND NHL 001, PIVOTAL TRIAL OF LISOCABTAGENE MARALEUCEL (JCAR017) IN R/R AGGRESSIVE NHL
EHA Learning Center, Jeremy Abramson, 214448
HIGH, DURABLE MINIMAL RESIDUAL DISEASE (MRD) NEGATIVITY WITH VENETOCLAX + RITUXIMAB IN RELAPSED/REFRACTORY CLL: MRD KINETICS AND RESPONSES IN CYTOGENETIC RISK GROUPS IN PTS FROM PHASE 3 MURANO STUDY
EHA Learning Center, Peter Hillmen, 214452
LENTIGLOBIN GENE THERAPY FOR TRANSFUSION-DEPENDENT Β-THALASSEMIA (TDT) IN PATIENTS WITH NON-Β0/Β0 GENOTYPES: UPDATED RESULTS FROM NORTHSTAR-2
EHA Learning Center, Franco Locatelli, 214455
CHOICES: A RANDOMIZED PHASE II TRIAL FOR IMATINIB VS HYDROXYCHLOROQUINE PLUS IM FOR PATIENTS WITH CML IN MCYR WITH RESIDUAL DISEASE DETECTABLE BY Q-PCR
EHA Learning Center, Gillian Horne, 214490
MICRORNA-155 (MIR-155) INHIBIT T LYMPHOCYTE PRENYLATION TO PROTECT AGAINST ACUTE GRAFT VERSUS HOST DISEASE (AGVHD)
EHA Learning Center, Xiaoxiao Wang, 214528
PAX5-ELN ONCOPROTEIN PROMOTES MULTISTEP B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN MICE
EHA Learning Center, Cyril Broccardo, 214531
EFFICACY OF VENETOCLAX AS A SINGLE AGENT AND IN COMBINATION WITH IBRUTINIB IN REFRACTORY OR RELAPSED T-PROLYMPHOCYTIC LEUKEMIA
EHA Learning Center, Christoph Kornauth, 214534
COMPLEMENT C3 AND C4 ARE ASSOCIATED WITH POSTNATAL VENOUS THROMBOSIS
EHA Learning Center, Anders Dahm, 214540
HEPCIDIN MIMETIC PTG-300 FOR TREATMENT OF INEFFECTIVE ERYTHROPOIESIS AND CHRONIC ANEMIA IN HEMOGLOBINOPATHY DISEASES
EHA Learning Center, Greg Bourne, 214543
ARRAYED MOLECULAR BARCODING IDENTIFIES TNFSF13 AS A POSITIVE REGULATOR OF ACUTE MYELOID LEUKEMIA-INITIATING CELLS
EHA Learning Center, Marion Chapellier, 214603
HIGH RATE OF COMPLETE RESPONSE BUT MINIMAL RESIDUAL DISEASE STILL DETECTABLE AFTER FIRST-LINE TREATMENT COMBINING OBINUTUZUMAB AND IBRUTINIB IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): ICLL07 FILO TRIAL
EHA Learning Center, Pierre Feugier, 214451
SYNTHETIC LETHAL SCREENING IDENTIFIES CHK1 INHIBITION AS AN EXPLOITABLE VULNERABILITY IN EZH2 DEFICIENT T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA
EHA Learning Center, Theresa Elizabeth Leon, 214495
FINAL RESULTS OF THE DESTINY STUDY OF DE-ESCALATION AND STOPPING TREATMENT IN CHRONIC MYELOID LEUKAEMIA
EHA Learning Center, Richard Clark, 214524
TH17 CELLS IN CLASSICAL HODGKIN LYMPHOMA ARE SUPPRESSED VIA THE PD1-PDL1 AXIS AND MAY PLAY AN IMPORTANT ROLE IN THE ACTION OF PD1 CHECKPOINT INHIBITORS
EHA Learning Center, Joseph Taylor, 214533
LUSPATERCEPT INHIBITS PSMAD2/3 SIGNALING AND PROMOTES ERYTHROID MATURATION THROUGH A GATA1 DEPENDENT MECHANISM
EHA Learning Center, Pedro Martinez, 214542
IL1RAP POTENTIATES MULTIPLE ONCOGENIC SIGNALING PATHWAYS IN AML
EHA Learning Center, Kelly Mitchell, 214602
REDUCED FIBROBLASTIC RETICULAR CELL EXPRESSION OF TISSUE-RESTRICTED ANTIGENS IMPAIRS PERIPHERAL REGULATION OF SELF-REACTIVE T CELLS DURING ACUTE GRAFT-VERSUS-HOST DISEASE
EHA Learning Center, Simone Dertschnig, 214605
PLATELET ADHESION UNDER FLOW CONDITION IS SIGNIFICANTLY AFFECTED BY HEMATOCRIT LEVELS IN POLYCYTHEMIA VERA PATIENTS
EHA Learning Center, Sara Gamba, 214607

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings